United States Pharmaceuticals & Healthcare Report Q2 2018
Tax reform in the US will influence many areas of pharmaceutical company activity in 2018, but will not bring the fullrange of benefits expected by some stakeholders. Although the statutory corporate tax rate will almost halve, the average effectiverate will only decline by a few percentage points. Other countries are also lowering their tax rates, and the full details of the changesin the US have yet to be fully considered. In addition, many foreign firms that generate high levels of profit in the US are alsobenefitting from the reforms.